BACKGROUND: Fingolimod is approved for the treatment of highly active relapsing-remitting multiple sclerosis in Europe. There is limited information on its effectiveness and safety in clinical practice within the UK. OBJECTIVE: To evaluate retrospectively the effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis who were prescribed fingolimod by UK neurologists within the National Health Service. METHODS: This was a multicentre, observational study conducted in the UK. Patients were initiated on fingolimod 0.5 mg 12 months before inclusion in the study. Key efficacy outcomes included annualised relapse rate and the proportion of patients free from relapses, disability progression and clinical and radiological disease activity at 12 months following fingolimod initiation. Resource utilisation and safety outcomes were also assessed. RESULTS: In 12 months of treatment with fingolimod, the mean annualised relapse rate was reduced by 79%, the majority of patients were free from relapses (83.7%). Based on limited data, most patients were free from disability progression and clinical and radiological disease activity. More than 90% of patients continued on fingolimod. Lymphocyte count reductions and liver enzyme increases were observed. CONCLUSION: Fingolimod was effective in reducing the disease activity in relapsing-remitting multiple sclerosis patients requiring an escalation from first-line therapies who were prescribed fingolimod in clinical practice in the UK.
BACKGROUND: Fingolimod is approved for the treatment of highly active relapsing-remitting multiple sclerosis in Europe. There is limited information on its effectiveness and safety in clinical practice within the UK. OBJECTIVE: To evaluate retrospectively the effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis who were prescribed fingolimod by UK neurologists within the National Health Service. METHODS: This was a multicentre, observational study conducted in the UK. Patients were initiated on fingolimod 0.5 mg 12 months before inclusion in the study. Key efficacy outcomes included annualised relapse rate and the proportion of patients free from relapses, disability progression and clinical and radiological disease activity at 12 months following fingolimod initiation. Resource utilisation and safety outcomes were also assessed. RESULTS: In 12 months of treatment with fingolimod, the mean annualised relapse rate was reduced by 79%, the majority of patients were free from relapses (83.7%). Based on limited data, most patients were free from disability progression and clinical and radiological disease activity. More than 90% of patients continued on fingolimod. Lymphocyte count reductions and liver enzyme increases were observed. CONCLUSION: Fingolimod was effective in reducing the disease activity in relapsing-remitting multiple sclerosis patients requiring an escalation from first-line therapies who were prescribed fingolimod in clinical practice in the UK.
Authors: Peter A Calabresi; Ernst-Wilhelm Radue; Douglas Goodin; Douglas Jeffery; Kottil W Rammohan; Anthony T Reder; Timothy Vollmer; Mark A Agius; Ludwig Kappos; Tracy Stites; Bingbing Li; Linda Cappiello; Philipp von Rosenstiel; Fred D Lublin Journal: Lancet Neurol Date: 2014-03-28 Impact factor: 44.182
Authors: Carrie M Hersh; Claire Hara-Cleaver; Richard A Rudick; Jeffrey A Cohen; Robert A Bermel; Daniel Ontaneda Journal: Int J Neurosci Date: 2014-10-29 Impact factor: 2.292
Authors: Ludwig Kappos; Ernst-Wilhelm Radue; Paul O'Connor; Chris Polman; Reinhard Hohlfeld; Peter Calabresi; Krzysztof Selmaj; Catherine Agoropoulou; Malgorzata Leyk; Lixin Zhang-Auberson; Pascale Burtin Journal: N Engl J Med Date: 2010-01-20 Impact factor: 91.245
Authors: Jeffrey A Cohen; Frederik Barkhof; Giancarlo Comi; Hans-Peter Hartung; Bhupendra O Khatri; Xavier Montalban; Jean Pelletier; Ruggero Capra; Paolo Gallo; Guillermo Izquierdo; Klaus Tiel-Wilck; Ana de Vera; James Jin; Tracy Stites; Stacy Wu; Shreeram Aradhye; Ludwig Kappos Journal: N Engl J Med Date: 2010-01-20 Impact factor: 91.245
Authors: Marco A Zarbin; Lee M Jampol; Rama D Jager; Anthony T Reder; Gordon Francis; William Collins; Dejun Tang; Xiaoli Zhang Journal: Ophthalmology Date: 2013-03-24 Impact factor: 12.079
Authors: Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky Journal: Ann Neurol Date: 2011-02 Impact factor: 10.422
Authors: Francisco Barrero; Javier Mallada-Frechin; María Luisa Martínez-Ginés; María Eugenia Marzo; Virginia Meca-Lallana; Guillermo Izquierdo; José Ramón Ara; Celia Oreja-Guevara; José Meca-Lallana; Lucía Forero; Irene Sánchez-Vera; María José Moreno Journal: PLoS One Date: 2020-04-02 Impact factor: 3.240
Authors: S Batista; C C Nunes; J J Cerqueira; Ana Martins Silva; J Correia de Sá; J Ferreira; M T Mendonça; J Pinheiro; V Salgado; A S Correia; J Sequeira; A Costa; L Sousa Journal: Neurol Sci Date: 2020-09-30 Impact factor: 3.307